Novartis has signed an exclusive strategic licence agreement for Arvinas鈥 ARV-766, a new treatment for prostate cancer.

ARV-766 is an investigational, orally bioavailable second-generation PROTAC androgen receptor (AR) degrader.

In preclinical studies, it has shown potential against wild-type androgen receptor tumours, as well as those with AR mutations or amplification, which can lead to resistance to current AR-targeted therapies.

The transaction also encompasses an asset purchase agreement for Novartis to acquire Arvinas鈥 preclinical AR-V7 programme.

Novartis will assume full responsibility for the global clinical development and marketing of ARV-766.

Novartis will hold all rights for executing the research, development, manufacture and marketing of the AR-V7 programme.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Arvinas is entitled to receive an upfront payment of $150m and $1.01bn in milestone payments on meeting development, regulatory and commercial goals, along with tiered royalties.

Goldman Sachs is the exclusive financial adviser to Arvinas.

Arvinas chairperson, president and CEO John Houston stated: 鈥淲e are thrilled to partner with an organisation that shares our dedication to delivering transformative medicines to patients with significant unmet needs.

鈥淲e believe the expertise and scale of Novartis will broaden the development of ARV-766 and its potential to be a first and best-in-class treatment for patients with prostate cancer. This strategic transaction also further validates our innovative PROTAC protein degrader platform and its potential to deliver new treatments.鈥

The latest development comes after Novartis exercised an option for the acquisition of all outstanding capital stock of IFM Therapeutics subsidiary IFM Due for $835m.

天美传媒app Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The 天美传媒app Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don鈥檛 miss your chance to stand out鈥攕ubmit your entry today!

Nominate Now